Table 1 Clinical characteristics in our cohort.

From: Identification of early warning biomarkers for type 4 cardio-renal syndrome based on bioinformatics analysis and secreted proteins

Clinical variables

Control (n = 55)

CKD (n = 62)

CRS4 (n = 51)

P value (control vs. CKD)

P value (control vs. CRS4)

P value (CKD vs. CRS4)

Age (year)

56.58 ± 8.36

60.55 ± 10.80

60.24 ± 8.13

0.056

0.107

0.982

Female/male (n)

29/26

34/28

25/26

0.819

0.703

0.538

Hypertension (n, %)

6 (10.91%)

29 (46.77%)

27 (52.94%)

< 0.001

< 0.001

0.514

Diabetes (n, %)

0 (0%)

12 (19.35%)

12 (23.53)

< 0.001

< 0.001

0.589

Cholesterol (mmol/L)

3.67 ± 0.95

4.15 ± 0.89

4.36 ± 0.94

0.015

< 0.001

0.470

LDL (mmol/L)

2.41 ± 0.60

2.31 ± 0.56

2.45 ± 0.57

0.618

0.932

0.406

LVEF (%)

67.97 ± 9.23

63.77 ± 6.61

54.92 ± 12.32

0.047

< 0.001

< 0.001

cTnT (ng/mL)

0.006 ± 0.003

0.009 ± 0.004

0.010 ± 0.004

< 0.001

< 0.001

0.410

NT-proBNP (pg/mL)

56.21 ± 26.27

85.56 ± 42.86

219.0 ± 130.6

< 0.001

< 0.001

< 0.001

eGFR (ml/min/1.73m2)

88.66 ± 8.91

33.79 ± 11.25

30.30 ± 12.43

< 0.001

< 0.001

0.275

CKD stage 3 (n, %)

0 (0%)

36 (58.06%)

24 (47.06%)

< 0.001

< 0.001

0.243

CKD stage 4 (n, %)

0 (0%)

21 (33.87%)

22 (43.14%)

< 0.001

< 0.001

0.313

CKD stage 5 (n, %)

0 (0%)

5 (8.06%)

5 (9.80%)

0.031

0.017

0.746

Back to article page